A lecture by Dr. Patrick Treacy to the IADA Conference in Alexandria, Egypt, titled “The Discovery of Hyaluronidase and My Advocation of Its Use in Aesthetic Medicine” blends historical science with practical applications
:1. Introduction: Why Hyaluronidase Matters
• Context: It opens with the aesthetic medicine boom, noting the dominance of hyaluronic acid (HA) fillers (e.g., Juvederm, Restylane, a $6 billion segment). He stresses hyaluronidase’s role as a “safety net,” making fillers reversible and safer, aligning with his JCCP leadership on patient safety.
2. Historical Discovery of Hyaluronidase
Treacy, with his Living History lens, vividly traces the enzyme’s origins, crediting key figures:
• Félix Duran-Reynals (1928):
o Describes his Rockefeller Institute experiments, injecting bacterial extracts into rabbit skin and observing a “spreading factor” that enhanced dye diffusion. Often called a “eureka moment” for tissue permeability.
o Highlight Duran-Reynals’ insight that this factor, later found in testes and venom, was enzymatic, published in Comptes Rendus (1928).
• Ernst Chain and Edward McIlwain (1940):
o Explain how Chain, a penicillin Nobel laureate, named “hyaluronidase” in a Biochemical Journal paper, linking it to HA breakdown after Karl Meyer’s 1934 HA discovery.
o Note Chain’s purification of testicular hyaluronidase, confirming its β-1,4 cleavage of HA into tetrasaccharides.
• Karl Meyer’s Role (1940s–1971):
o Clarify Meyer’s HA discovery (1934, with John Palmer) provided the substrate, while his 1971 Methods in Enzymology review classified hyaluronidases (mammalian, leech, bacterial), standardizing their study.
o
• Early Uses: Mention 1950s applications in orthopedics (e.g., joint injections) and ophthalmology, setting the stage for aesthetics’ adoption in the 2000s.
3. Hyaluronidase in Aesthetic Medicine
Treacy’s advocacy, drawing on his 30+ years pioneering filler complication treatments worldwide:
• Mechanism:
o Explains hyaluronidase (e.g., Hyalase, Vitrase) as an enzyme hydrolyzing HA’s β-1,4 bonds, dissolving fillers in 4–48 hours. He notes its sources (bovine, ovine, recombinant) and typical dose (50–150 units per ml of filler).
• Applications:
o Complication Management: Highlight vascular occlusion, a rare (0.01–0.1% of cases) but serious filler risk. Treacy details his protocol: injecting 150–300 units hyaluronidase to restore blood flow within minutes, citing his AMEC-winning research.
o Overcorrection: Describe smoothing lumps or asymmetry (e.g., overfilled lips), reassuring patients fillers aren’t permanent.
o Aesthetic Refinement: Note off-label uses, like dissolving old filler for a fresh look, enhancing natural results.
• Safety Profile:
o Acknowledge low risks (allergic reactions in ~0.1%, redness) but stress proper training, as he teaches globally.
o Warn against overuse degrading natural HA, causing temporary laxity—a nuance for practitioners.
• Market Impact: Argue that hyaluronidase’s reliability drives filler demand as patients feel safer. He cites stats (e.g., 3.5 million HA filler procedures yearly, per ISAPS) to echo LOOKS’s expansion goals.
4. Treacy’s Advocacy
• Personal Journey: This shows how he adopted hyaluronidase early, learning from the 1990s filler mishaps to refine protocols. He mentions high-profile cases (e.g., advising Michael Jackson against surgery, per your 72 Films talks) to show his safety-first ethos.
• Research Contributions: References his papers on filler complications, advocating hyaluronidase’s inclusion in every injector’s toolkit. He cites training 8,000+ clinicians, ensuring its global adoption.
source
